Recent large-scale clinical trials such as the EMPA-REG Study [9], CANVAS Program [10], Declare-TIMI 58 [11] have demonstrated that different types of SGLT-2 inhibitors significantly reduce the cardiovascular incidence/mortality and heart failure–related hospitalization rates in patients with T2DM and confirmed cardiovascular disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.